Step down one tier at a time, within a single brand, and change nothing else while you do it. Dropping from 6 mg to 3 mg in the same product line roughly halves the nicotine you actually absorb. Doing the same thing across two brands may not reduce your dose at all — and in at least one measured case it increases it.
A word about that title first. Nothing here makes nicotine safe, and no regulator has ever said otherwise. What “safely” can honestly mean on this page is narrower: reducing the number on the can without accidentally keeping your intake flat, and without walking into withdrawal you were not expecting. That is a real problem with a partly measurable answer, and it is what the rest of this covers.
It is also worth saying at the top that nobody regulates any of this. There is no label on a pouch can telling you how to come down, no maximum daily count, and no tobacco regulator anywhere publishes consumer guidance on choosing a pouch strength. Compare that with the licensed nicotine products further down this page, where the instructions are statutory and precise, and the gap is the single most striking thing in the material.
Halving the milligrams does roughly halve the dose — within one product line
The cleanest measurement we have of a one-tier step comes through Germany’s Federal Institute for Risk Assessment, which reproduced the figures from a pharmacokinetic study of three strengths of the same brand in its opinion of 7 October 2022. On extraction: “Nicotine extraction was found to be 56% and 59% for the 3 mg and 6 mg doses, with only 32% of the nicotine being extracted from snus.” On what reached the blood: “The peak concentrations in blood for the 3 mg and 6 mg doses were 7.7 ng/ml and 14.7 ng/ml, respectively.”
The UK’s Committee on Toxicity reports the same study in absolute terms: “Nicotine extraction from the 3 and 6 mg nicotine pouches was reported as 1.5 mg (95% confidence interval [CI]: 1.3–1.8 mg, p = 0.002) and 3.5 mg (95% CI: 3.0–4.0 mg, p = 0.002), respectively.”
So halving the label halved the peak, near enough — 7.7 against 14.7 ng/ml. That arithmetic is mine, not the study’s; neither the paper nor either regulator divides one by the other. The direction of the small error is in your favour, though: the fraction extracted barely moved between the two strengths, so a 3 mg pouch gives you a touch more than half the peak rather than a touch less. Two things to carry forward. The study was funded by the brand’s manufacturer, Swedish Match. And it was a single-dose crossover in abstinent users, not a taper — nobody has ever run a study in which people actually stepped down over time.
There is a useful dose-response note in the same BfR opinion, measured at exactly the step this page is about: on heart rate, “the changes in the 6 mg dose group are significantly higher than those in the 3 mg dose group.” The step is doing something physiological, not just arithmetical.
Across brands, the ladder does not exist
This is the finding that should change how you plan a step down, and it is stated outright in a study run by a pouch manufacturer. British American Tobacco’s own crossover trial put six products through 35 subjects with a 60-minute hold, and concluded:
“Plasma nicotine concentration was not associated with the nicotine contents of the NPs.”
“Although the NPs used by participants in this study spanned a range of nicotine contents from 6 to 10 mg nicotine per pouch, a higher nicotine content did not necessarily appear to give rise to a higher Cmax and AUC0–6h.”
The numbers behind that sentence are blunt. A 6 mg pouch produced a peak of 17.5 ng/mL; a 10 mg pouch from a different brand produced 11.9. The lower number on the can delivered about half again as much nicotine. The authors’ explanation: “The various products have different features (e.g. pouch dimensions, pH and pouch constituents) that may enable the 6 mg product to provide a higher nicotine blood plasma concentration than some products with higher nicotine contents.” That study was supported by BAT, and every author was a BAT or RAI employee or contractor — which, if anything, makes the finding harder to dismiss, since it cuts against the usefulness of its own industry’s labelling.
An independent German study reached the same conclusion in its own words. Mallock-Ohnesorg and colleagues, funded by intramural BfR money with no commercial relationships declared, found that their results “speak against a linear relationship between nicotine delivery and nicotine content in the pouch, visible in the relative bioavailability ranging from 70% to 165%”, and that “the Cmax does not increase proportionally with the nicotine content.” Crucially, they also reconciled the two halves: “Lunell et al. have investigated three different nicotine strengths from the same brand and the Cmax increase was almost linear in relation to the nicotine content.”
Same brand, roughly linear. Different brands, not a ladder at all. That is the whole practical rule.
The number on the can is approximate anyway
Two independent papers have weighed what is actually in the pouch, and neither flatters the label.
The BfR-funded study found “the pouches only contained between 80% and 90% of the declared nicotine content”, with measured contents of 4.8 ± 0.4 mg, 16.3 ± 3.1 mg and 27.1 ± 0.2 mg for pouches declared at 6, 20 and 30 mg.
A 2026 dissolution study in Scientific Reports went product by product across seven mint pouches: “For on!, Rogue, and Volt nicotine pouches, the calculated nicotine content was slightly higher than the target… The nicotine content in Zyn and Loop pouches was found to be 5.4 mg/pouch and 9.1 mg/pouch, slightly below the target of 6 mg/pouch and 9.4 mg/pouch. However, the calculated nicotine content for Velo and Dryft (both labeled as 7 mg) was significantly lower than the target, measuring 4.6 mg/pouch and 5.7 mg/pouch, respectively.”
Put those two measurements beside each other and you get the clearest illustration on this page. A pouch labelled 7 mg measured 4.6 mg. A pouch labelled 6 mg measured 5.4 mg. Someone “stepping down” from the first to the second would be stepping up by about 17% on the chemistry while the label told them they had gone down. I should flag that the senior author of that dissolution paper works for Altria, and that the published version I could read carried no funding or competing-interests statement at all — not a declaration of none, simply absent. That is worth knowing about a paper whose findings happen to be unflattering to two competitors.
mg per pouch and mg per gram do not move together
One brand — Nordic Spirit — publishes both figures to consumers, which makes it the only worked example available. Its own FAQ gives 3 mg and 4 mg minis at 9 mg/g, a 6 mg standard at 9 mg/g, 9 mg at 14, 11 mg at 17 and 17 mg at 24.
Follow a step down that ladder and the trap is obvious. Going from the 6 mg standard to the 4 mg mini cuts the milligrams per pouch by a third and leaves concentration completely unchanged at 9 mg/g — you have simply bought a smaller pouch. Going from 9 mg to 6 mg cuts both, concentration falling from 14 mg/g to 9. Two moves that each look like “one step down” are not the same change. We go through this distinction properly in mg per pouch vs mg per gram.
Pouch mass is the reason the two measures diverge so wildly between brands. ZYN’s own FAQ states that “One ZYN pouch weighs approximately 0.4 grams”, while BfR’s cross-brand survey found “The median weight per pouch was 0.6 g and the nicotine content per pouch was 9.48 mg”, across a range running from 0.25 to over 1 g. Both are correct. They are just not measuring the same thing.
Shortening the hold is a weaker lever than it feels
The obvious alternative to dropping the strength is keeping the pouch in for less time. The release data say this buys you less than you would expect, because almost all of the nicotine comes out early.
In the dissolution study above: “In the profile region between 0 and 20 min, we observed a total nicotine percent release of 93% for Zyn, 87% for on!, 84% for Rogue, 71% for Volt and Velo, 66% for Dryft, and 48% for Loop nicotine pouch products.” BfR reports the same shape from its own survey: “most of the nicotine is released within the first 20 minutes.”
Cutting a 30-minute hold to 15 therefore removes the tail, not half the dose. It also varies enormously by brand — at twenty minutes one product had released 93% and another 48%, so “half the time” means two completely different things in two different cans. One caution: those are in-vitro release figures measured in artificial saliva, and they run well ahead of what a person actually absorbs. In the human studies, 60 minutes of use extracted only around 50–59% of the nicotine in the pouch. Do not convert a release percentage into a delivered dose. For what the hold time does and does not control, see how long to keep a pouch in.
The four levers, ranked by how well each is actually evidenced
| Lever | What it changes | How well evidenced | Practical verdict |
|---|---|---|---|
| Drop one tier within the same brand | Roughly proportional cut in peak and total nicotine | Strongest — measured directly at 3 vs 6 mg, same product line, and restated by two regulators | The reliable move |
| Drop a tier by switching brand | Unpredictable; can increase your dose | Explicitly contradicted — “not associated with the nicotine contents” | Avoid while stepping down |
| Use fewer pouches per day | Total daily intake, directly | No pouch data at all; it is how every licensed oral nicotine product tapers | Probably the most underrated |
| Shorten the hold | Removes the late tail only | Release curves are solid; the in-mouth translation is not | Marginal, and brand-dependent |
What regulated nicotine products do, and what pouches do not
The contrast here is built entirely from label text, and it is the sharpest thing in this article.
A licensed nicotine patch comes with a strength ladder written into the summary of product characteristics: “Step 1 Nicorette Invisi 25 mg Patch First 8 weeks / Step 2 Nicorette Invisi 15 mg Patch Next 2 weeks / Step 3 Nicorette Invisi 10 mg Patch Last 2 weeks”, followed by “Gradual weaning from the patch should then be initiated.” Note the shape: eight weeks at full strength, then two and two coming down. The taper is the short part.
The oral forms taper by count rather than strength, with one exception. The 4 mg lozenge label says: “For those using the 4 mg lozenges, switching to the 2 mg lozenges may be helpful when stopping treatment or reducing the number of lozenges used each day.” It also tells you which strength to start on — “if the patient smokes 20 or less cigarettes a day, 2 mg nicotine lozenge is indicated” — and sets a hard ceiling: “Most patients require 8 to 12 lozenges per day, not to exceed 15 lozenges.”
Now the pouch side. ZYN’s FAQ gives a pouch weight and two strengths and no daily maximum, no mg-per-gram figure and no guidance on reducing strength. VELO’s UK FAQ lists its strengths, tells you a pouch can stay under the lip “for up to 30 minutes”, and likewise gives no daily cap and no step-down advice. The only maker-published interval instruction anywhere in our files is a single “use no more than one sachet for 2 hours” from one brand. Meanwhile Health Canada, which licenses one pouch as a medicine, authorises it at “1.0 Pouch, 1 to 15 times daily” — a regulator-set daily maximum that no recreational pouch carries.
VELO’s own site is also where the most useful caveat on this page comes from, in the manufacturer’s words: “VELO contains nicotine and is addictive.”
Two findings that cut against the premise of this article
I would rather print these than leave them out.
The FDA considered a stepped approach to nicotine reduction and rejected it. In its proposed nicotine product standard for cigarettes (90 FR 5032, 16 January 2025), the agency wrote: “FDA is proposing an immediate nicotine reduction (i.e., single target) approach to reach the proposed maximum nicotine level (rather than a gradual reduction, or stepped-down, approach) to limit additional toxicant exposure.” Its reason was compensation — it expected “very little or no compensatory smoking… with an immediate reduction approach, as opposed to a gradual reduction approach which showed evidence of increased compensatory smoking.”
Two qualifications belong with that. The proposed standard does not cover pouches: FDA states it is “not including noncombusted non-cigarette tobacco products, such as electronic nicotine delivery systems (ENDS)… and smokeless tobacco products, in the scope of this proposed product standard.” And the underlying literature is more equivocal than the agency’s sentence implies — a head-to-head analysis of gradual against immediate reduction in cigarettes, by researchers funded by the same federal programme, found “minimal if any compensatory smoking for both the gradual and immediate reduction approaches.”
The only randomised comparison of two pouch strengths pointed the other way. The Cochrane review of oral nicotine pouches, evidence current to January 2025, reports: “One study (NCT04250727, unclear risk of bias, comparing 6 mg versus 3 mg dose) reported cessation at four-week follow-up; more participants quit in the higher-dose group (2 of 15 participants) compared to the lower-dose group (0 of 15 participants).” Two people out of fifteen against none out of fifteen proves nothing whatsoever — but a page telling you to step down ought to mention that the one trial resembling the question found the opposite.
Cochrane’s overall assessment of the field is worth quoting in full, because it is the most authoritative sentence available on what pouches do and do not do: “There is limited available evidence on the use of oral nicotine pouches (ONP) for cessation or reduction of cigarette use in people who smoke. There is no evidence on the use of ONP for cessation or reduction of other tobacco or non-pharmaceutical nicotine products.” The whole evidence base is four small studies totalling 284 people, three of them at high risk of bias, with key outcomes rated “Very low” certainty.
What nobody has measured
Three gaps, all of which matter for anyone planning a taper.
No study anywhere has tested stepping down pouch strength. Every pharmacokinetic comparison between strengths is a single-dose crossover in abstinent users; Cochrane’s search to January 2025 turned up nothing longitudinal.
No study has measured compensation in pouch users. Whether people given a weaker pouch take more of them, hold them longer, or move the pouch around to pull more out has never been tested. The headroom is certainly there: in the 60-minute human studies, roughly 40–50% of the pouch’s nicotine was still in it when it came out. A user who holds longer or chews can extract some of that without changing the number on the can — a physical mechanism by which a step down can be quietly undone.
There is no published withdrawal time course. Not from the FDA, not from COT, not from BfR, and not in any of the licensed-medicine labels I read. The labels give symptom lists with frequency categories and no onset, peak or duration. If you want to know how long a rough patch lasts, no regulator has published an answer.
What withdrawal actually looks like, in a regulator’s words
The fullest official list comes from the patch label, and its scope matters: it describes nicotine withdrawal on stopping smoking, in the label of a licensed medicine, not withdrawal from reducing pouch strength. With that caveat, it reads:
“irritability/aggression, dysphoria/depressed mood, anxiety, restlessness, poor concentration, increased appetite/weight gain, urges to smoke (cravings), night-time awakenings/sleep disturbance, decreased heart rate, dizziness, presyncopal symptoms, cough, constipation, gingival bleeding or nasopharyngitis”
The mouthspray label adds the line that explains why people abandon tapers: “Nicotine craving, which is recognised as a clinically relevant symptom, is an important element in nicotine withdrawal after smoking cessation.”
So how would I actually do it
Given everything above, the version of a step down that the evidence supports is unglamorous.
Pick one brand and stay in it. This is the only rule with hard data behind it, and switching brands mid-taper destroys the only reliable relationship between the label and the dose.
Move one tier at a time, and check the mg-per-gram as well as the mg-per-pouch if your brand publishes both — Nordic Spirit is currently the only one that does to consumers. If a step changes only the pouch size, you have changed the format, not the dose.
Count your pouches, not just your milligrams. It is how every licensed oral nicotine product in the world tapers, and it is the only variable you fully control. A step from 6 to 3 mg that comes with two extra pouches a day is not a step down.
Change one thing at a time. Flavour is a confound as well: the pooled analysis of pouch pharmacokinetics found that flavoured products delivered significantly more nicotine than unflavoured ones at the same strength, so changing flavour while you change strength muddies what you are measuring.
And hold the hold constant. Shortening it while you drop a tier makes the drop larger than you planned, which is not automatically a good thing if the result is a rough week you give up on.
None of that makes a pouch safe, and none of it makes a pouch a quitting aid. On the latter, I would simply quote the manufacturer: ZYN’s own FAQ answers the question “Will ZYN help me quit smoking?” with “ZYN is a convenient way to enjoy nicotine without the smoke or spit. It can be used as an alternative to smoking or dipping, but for those consumers concerned about the health effects of smoking or dipping, the best thing to do is quit.” If quitting is your goal rather than reducing, licensed nicotine replacement therapy has the labels, the schedules and the evidence that pouches do not — our piece on what the evidence says about quitting with pouches goes through that in detail.
Frequently asked questions
Is a 3 mg pouch half a 6 mg pouch?
Within the same brand and format, close to it — peak blood nicotine measured 7.7 against 14.7 ng/ml in the one study that tested both. Across brands, no.
How long should I spend on each tier?
Nobody knows, because no study has tested it. For reference only, the licensed patch label runs eight weeks at full strength, then two weeks per step down — but that is a different product, a different route and a cessation regimen.
Can I just use fewer pouches instead of dropping strength?
That is exactly what the licensed oral nicotine products do: they taper by count, with the strength switch offered only as an optional aid. There is no pouch-specific evidence either way, but it is the better-precedented approach.
Will I get withdrawal symptoms from dropping one tier?
No published study has measured it. The symptom lists above come from medicine labels describing withdrawal on stopping smoking entirely, which is a much larger change than one tier.
Does the label on the can tell me what I am getting?
Approximately. Measured contents have come in between roughly 66% and 103% of the declared figure across the published analyses, and two brands labelled identically at 7 mg measured 4.6 and 5.7 mg. Treat the number as a tier marker within one brand, not a dose.
Sources
- Bundesinstitut für Risikobewertung, Updated BfR Opinion No. 023/2022, Health risk assessment of nicotine pouches, 7 October 2022 — extraction and peak-concentration figures at 3 and 6 mg, median pouch weight, heart-rate dose response, release timing.
- Committee on Toxicity, TOX/2022/22, Nicotine pouches (updated), March 2022 — extracted nicotine in mg at 3 and 6 mg. COT also records the conclusion that pouches of 6 mg or more “could be used as a smoking reduction/cessation tool”; that is COT reporting the manufacturer-funded authors’ own conclusion, not COT endorsing it.
- McEwan M, Azzopardi D, Gale N, Camacho OM, Hardie G, Fearon IM, Murphy J. “A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette.” European Journal of Drug Metabolism and Pharmacokinetics 2022;47:211–221. Full text. Funding: “The study was supported by British American Tobacco (Investments) Limited, the manufacturer of Lyft and Velo smokeless oral nicotine pouches.” Competing interests: all authors BAT or RAI employees, or a contracted consultant.
- Mallock-Ohnesorg N, Rabenstein A, Stoll Y, et al. “Small pouches, but high nicotine doses—nicotine delivery and acute effects after use of tobacco-free nicotine pouches.” Frontiers in Pharmacology 2024;15:1392027. Full text, 22 May 2024. Funding: intramural BfR grant BfR-CPS-08-60-0102-02.P606. Conflict of interest: none declared.
- Platt SP, Gonzales CM, Pokharel P, et al. “Dissolution and physical characterization of oral nicotine pouch products.” Scientific Reports 2026;16:4406. Full text, 6 January 2026. No funding statement and no competing-interests statement appear on the published page; the corresponding author’s affiliation is Altria Client Services LLC.
- Hartmann-Boyce J, Tattan-Birch H, Brown J, et al. “Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products.” Cochrane Database of Systematic Reviews 2025, Issue 10, Art. No. CD016220. Full text. Funded by the National Cancer Institute (NIH) and FDA Center for Tobacco Products, award 2U54CA229974. Evidence current to January 2025.
- FDA, “Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products”, proposed rule, 90 FR 5032, 16 January 2025.
- Nicorette Invisi 25 mg Patch, Summary of Product Characteristics, McNeil Products Limited, text revised 29 April 2026 — stepped schedule and withdrawal symptom list.
- Nicorette Fruit 4 mg Lozenge, Summary of Product Characteristics, McNeil Products Limited, text revised 23 June 2026 — the 4 mg to 2 mg switch and the daily ceiling.
- ZYN US FAQ and VELO UK FAQ — manufacturer statements on strengths, pouch weight, hold time and the absence of any daily maximum or step-down guidance. Both read 4 October 2026.
Where this page divides one published figure by another — the halving arithmetic, the per-gram implied pouch weights — that calculation is ours and is labelled as such. No source performs it. Last verified 4 October 2026.
Related reading: the complete mg guide, every brand’s strength scale compared, what “extra strong” actually means, pouch pH and why it changes the hit, and how nicotine pouches actually work. If you are choosing a starting point rather than coming down, see choosing your first strength.